GSK and Genmab receive EU authorisation for Arzerra™ (ofatumumab) as first-line treatment for chronic lymphocytic leukaemia (CLL) in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy | 2014 | Press releases | Media | GlaxoSmithKline
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.